The company said that research is in early stages to focus on the safety of treatment and how patients tolerate their first patient. The patient was in Sheffield, spinal cord and brain injury rehabilitation center in Atlanta, a study of seven sites in the United States. To participate, patients must have two weeks before the accident.
"When we started working with human embryonic stem cells in 1999, many observers predict it will take decades, clinical trials are approved cell therapy in humans," said Dr. Thomas B. Okarma, Geron's president , CEO, said in a statement.
Despite the technical steps, it is a drug candidate and long-term market has proven to be a long way to go. Before the validity of the test, hopefully, in the early stages of research for many years.
Embryonic stem cells in the center of controversy because the research funding, the destruction of embryos, which some believe is close to abortion. However, many researchers believe that embryonic stem cells, stem cells are the most common because it can be any cell type. Although federal funding for stem cell research has been struggling for words that Geron uses no state funds.
The company said it intends to participate in a national study on the site 80-10 patients. Test takes about two years, each patient is studied for a year. The first phase of clinical trials, particularly to examine the safety of a therapy. "A successful test would be safer and more studies on lead effectively.
The treatment - known as GRNOPC1 - contains cells called oligodendrocyte progenitor cells. oligodendrocyte progenitor cells in a switch of cell type on the myelin sheath, the impulse to produce along the nerve pathways. If GRNOPC1 engineering, stem cells created at the expense of patients, the spine in terms of new oligodendrocytes, may be allowed for the new season.
The treatment is injected into the backs of the patients one or two weeks, suffered injuries of the thorax between the third and tenth, about half of the back. Later part of the study in SCI patients with less damage to other parts of the spine.
Geron, Menlo Park, California's embryonic stem cell therapy in the treatment of several companies focused on healthcare. Advanced Cell Technology hopes to develop embryonic stem cells for treatment of pigmented epithelial cells or retinal pigment epithelial cells of the retina. This therapy for the treatment of the star Garth disease, a genetic disease that children and adults can lead to blindness effect.
At the same time, companies like StemCells, other companies focus on adult stem cells that can be a person "of the skin together.
No comments:
Post a Comment